JohnM.McCartyMD

Oncology • Richmond, VA

VCU Massey Cancer Center Bone Marrow Transplantation Program

Join to view full profile

Dr. McCarty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCarty's full profile

Already have an account?

Office
1300 E Marshall St
Mailstop 981057
Richmond, VA 23298
Phone+1 804-828-4596

Fax+1 804-628-0827

Summary

Dr. John McCarty is the Medical Director of the Cellular Immunotherapy and Transplantation Program at VCUHS Massey Cancer Center in Richmond VA. He is also the head of the Cellular Immunotherapy Laboratory there. . He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 31 years. He also speaks multiple languages, including Spanish. He specializes in Cellular Immunotherapy such as CARt cells and in all forms of autologous and allogeneic stem cell transplantation. He is currently the G Watson James Endowed Professor of Hematology.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1993
Tufts Medical CenterResidency, Internal Medicine, 1986 - 1989
Icahn School of Medicine at Mount SinaiClass of 1986
Princeton UniversityAB, Biochemistry, Cum Laude, 1978 - 1982

Certifications & Licensure

VA State Medical License 1996 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

G Watson James Endowed Professor of Hematology Virginia Commonwealth University, 2018
Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Start of enrollment: 1997 Apr 01
Terminated
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome Start of enrollment: 2008 Jul 01
Completed
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) Start of enrollment: 2015 Aug 01
Completed
Phase 3
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Start of enrollment: 2015 Aug 01
Completed
Phase 2
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Start of enrollment: 2016 Dec 20
Completed
Phase 1, Phase 2
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501) Start of enrollment: 2016 Oct 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

87 citations
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
Bronwen E. Shaw, Antonio Jimenez-Jimenez, Linda J. Burns, Brent R. Logan, Farhad Khimani
Journal of Clinical Oncology. 2021-04-27
282 citations
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt, Luciano J. Costa, Jeffrey Schriber, John F. DiPersio, Richard T. Maziarz
Biology of Blood and Marrow Transplantation. 2014-03-01
19 citations
Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.
Lauren M. Curtis, Manuel B. Datiles, Seth M. Steinberg, Sandra A. Mitchell, Rachel Bishop
Haematologica. 2015-06-18

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Treatment of Acute Fibrinous Organizing Pneumonia Following Hematopoietic Cell Transplantation with Etanercept
K Miller, W B Clark, J M McCarty, A A Toor, H M Chung, Nature

Abstracts/Posters

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival
John M. McCarty, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

VCU Massey’s Cellular Immunotherapies and Transplant Program ExpandsJanuary 19th, 2023
Booster Shots Are Coming. Here’s What That Means for VirginiaAugust 20th, 2021
Virginia to Provide 3rd Dose of COVID Vaccine to Immunocompromised PeopleAugust 13th, 2021
Join now to see all